Transexuales: Conclusiones en suicidios, trombosis y evento cardiovascular (página 3)

35. Giltay EJ, Verhoef P, Gooren LJ, Geleijnse JM, Schouten EG & Stehouwer CD. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis 2003 168 139–146.

36. Go A, Hylek EM, Phillips KA, et al. Prevalence of atrial fibrillation: national implications for management and stroke prevention: the ATRIA study. JAMA 2001; 285: 2.370-2.375

37. Gómez Gil E. La atención a la transexualidad por la unidad de salud mental del Hospital Clínic de Barcelona en los últimos años. Cuad Med Psicosom Psiquiatr Enlace 2006; 78, 55-64.

38. Gunnell D, Frankel S. Prevention of suicide: aspirations and evidences. British medical journal, 1999, 308: 1227-1233.

39. Gupta S, et al. Factors associated with suicide attempts among patients with schizophrenia. Psychiatric services, 1998, 10: 1353-1355.

40. Guven ES, Guven S, Ayhan A. Comment on "Recurrent carcinoma in situ of a neovagina". Gynecol Oncol. 2004 Feb; 92 (2):728; 728-9.

41. Guven S, Guvendag Guven ES, Ayhan A, Gokoz A. Recurrence of high-grade squamous intraepithelial neoplasia in neovagina: case report and review of the literature. Int J Gynecol Cancer. 2005 Nov-Dec; 15 (6):1179-82.

42. H. A. Hassan, "Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia," Journal of Clinical Gastroenterology, vol. 29, no. 1, pp. 90–95, 1999.

43. Hawton K. Sex and suicide. Gender differences in suicidal behaviour. Br J Psychiatry 2000; 177: 484-485.

44. Hepp U, Klaghofer R, Burkhard-Kubler R, Buddeberg C (2002) [Treatment follow-up of transsexual patients. A catamnestic study]. Nervenarzt 73: 283–288.

45. Hiroi H, Yasugi T, Matsumoto K, Fujii T, Watanabe T, Yoshikawa H, Taketani Y. Mucinous adenocarcinoma arising in a neovagina using the sigmoid colon thirty years after operation: a case report. J Surg Oncol. 2001 May; 77 (1):61-4.

46. Hopkins MP, Morley GW. Squamous cell carcinoma of the neovagina. Obstet Gynecol. 1987 Mar; 69 (3 Pt 2):525-7.

47. Hulley S, Grady D, Bush T, Furbert C, Herrington D, Riggs B & Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association 1998 288 605–613. /jama.280.7.605)

48. Idrees MT, Deligdisch L, Altchek A. Squamous papilloma with hyperpigmentation in the skin graft of the neovagina in Rokitansky syndrome: literature review of benign and malignant lesions of the neovagina. J Pediatr Adolesc Gynecol. 2009 Oct; 22 (5):e148-55.

49. J. J. Trauscht-Van Horn, E. L. Capeless, T. R. Easterling, E. G. Bovill, "Pregnancy loss and thrombosis with protein C deficiency," American Journal of Obstetrics and Gynecology, vol. 167, no. 4 I, pp. 968–972, 1992.

50. J. W. Elliot, "The operative relief of gangrene of the intestine due to occlusion of the mesenteric vessels," Annals of Surgery, vol. 21, pp. 9–23, 1895.

51. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS: Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke; 1996 27(10): 1765-9.

52. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modi?e test for activated protein C resistance. Lancet 1994;344:1162–

53. Jung W, Anderson M, Camm AJ, Jordaens L, Petch MC et al. Recommendations for driving of patients with implantable cardioverter defibrillators. Eur Heart J 1997; 18: 1210-1219.

54. Kalbfleisch KR, Lehmann MH, Steinman RT, Jackson K, Axtell K, Schuger CD, Tchou PJ. Reemployment following implantation of the automatic cardioverter defibrillator. Am J Cardiol 1989 64(3): 199-202.

55. Kalev M, Day T, Van de Water N, Ockelford P. Screening for a prothrombotic diathesis in patients attending family planning clinics. N Z Med J1999;112:358–61.

56. Kanel WB, Abbott RD, Savage DD y cols.: Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982, 306:1018-1022.

57. Kaube H, Biemer E (1991) [Results of sex change operations in 30 transsexual patients: psychosocial and sexual adaptation–surgical complications]. Handchir Mikrochir Plast Chir 23: 276–278.

58. Kesteren PJM, Asscheman H, Megens JAJ & Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology 1997 47 337–342.

59. Kokcu A, Tosun M, Alper T, Sakinci M. Primary carcinoma of the neovagina: a case report. Eur J Gynaecol Oncol. 2011; 32 (5):588-9.

60. Kusumoto FM, Goldschlager N. Cardiac Pacing. N Engl J Med 1996; 334:89-98

61. Lande䮠M, Innala S (2000) Attitudes toward transsexualism in a Swedish national survey. Archives of Sexual Behavior 29: 375–388.

62. Lande䮠M, Wa଩nder J, Lundstro譠B (1998) Clinical characteristics of a total cohort of female and male applicants for sex reassignment: a descriptive study. Acta Psychiatrica Scandinavica 97: 189–194.

63. Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 2003;90:17–26.

64. Lawrence AA (2003) Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. Arch Sex Behav 32: 299–315.

65. Levesque H, Manchon ND, Moore N, Blanckard CE Byar DP, Jordan WP.Fulminant hepatitis due to cyproterone acetate. Lancet 1989; 1: 215-

66. Liebrich C, Reinecke-Lüthge A, Kühnle H, Petry KU. [Squamous cell carcinoma in neovagina at Mayer-Rokitansky-Küster-Hauser-syndrome]. Zentralbl Gynakol. 2006 Oct; 128 (5):271-4.

67. Lindemalm, D. K诲lin, and N. Uddenberg, "Long-term follow-up of "sex change" in 13 male-to-female transsexuals," Archives of Sexual Behavior, vol. 15, no. 3, pp. 187–210, 1986.

68. Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008;37:19–30.

69. Lowe MP, Ault KA, Sood AK. Recurrent carcinoma in situ of a neovagina. Gynecol Oncol. 2001 Mar; 80 (3):403-4.

70. M. Hoshiai, Y. Matsumoto, T. Sato et al., "Psychiatric comorbidity among patients with gender identity disorder," Psychiatry and Clinical Neurosciences, vol. 64, no. 5, pp. 514–519, 2010.

71. M. Land䥮, J. W࡬inder, G. Hambert, and B. Lundstr语, "Factors predictive of regret in sex reassignment," Acta Psychiatrica Scandinavica, vol. 97, no. 4, pp. 284–289, 1998.

72. M. S. C. Wallien, H. Swaab, and P. T. Cohen-Kettenis, "Psychiatric comorbidity among children with gender identity disorder," Journal of the American Academy of Child & Adolescent Psychiatry, vol. 46, no. 10, pp. 1307–1314, 2007.

73. María Fernández y Elena García-Vega. Análisis de algunas variables sociodemográfias en un grupo de personas transexuales. Norte de salud mental, 2014, vol. XII, nº 48: 26-35

74. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review.Contraception 2006;73:166–78.

75. Mueller A, Gooren L (2008) Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 159: 197–202.

76. Munkarah A, Malone JM Jr, Budev HD, Evans TN. Mucinous adenocarcinoma arising in a neovagina. Gynecol Oncol. 1994 Feb; 52 (2):272-5.

77. N. Okabe, T. Sato, Y. Matsumoto, Y. Ido, S. Terada, and S. Kuroda, "Clinical characteristics of patients with gender identity disorder at a Japanese gender identity disorder clinic," Psychiatry Research, vol. 157, no. 1–3, pp. 315–318, 2008.

78. Nakao J, Change WC, Murota SI, Orimo H. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis 1981;39:203–9.

79. O. Bodlund and G. Kullgren, "Transsexualism—general outcome and prognostic factors: a ve-year follow-up study of nineteen transsexuals in the process of changing sex," Archives of Sexual Behavior, vol. 25, no. 3, pp. 303–316, 1996.

80. Olsson SE y Moller AR. On the incidence and sex ratio of transsexualism in Sweden, 1972- 2002. Arch Sex Behav 2003; 32, 381-386

81. Pabinger and B. Schneider, "Thrombotic risk of women with hereditary antithrombin IIII, protein C and S deficiency taking oral contraceptives. THE GTH Study Group on Natural Inhibitors," Thrombosis and Haemostasis, vol. 71, no. 5, pp. 548– 552, 1994.

82. Polderman KH, Gooren LJ, Asscheman H, Bakker A & Heine RJ. Induction of insulin resistance by androgens and estrogens. Journal of Clinical Endocrinology and Metabolism 1994 79 265–271.

83. Post MS, Christella M, Thomassen LG, van der Mooren MJ, Van Baal WM, Rosing J, Kenemans P & Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 1116–1121.

84. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;28:1133–4.

85. Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Koopersberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM & Ockene J. Risks and bene?ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women"s Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321–333. /jama.288.3.321)

86. Rotmensch J, Rosenshein N, Dillon M, Murphy A, Woodruff JD. Carcinoma arising in the neovagina: case report and review of the literature. Obstet Gynecol. 1983 Apr; 61 (4):534-6.

87. Schult M, Hecker A, Lellé RJ, Senninger N, Winde G. Recurrent rectoneovaginal fistula caused by an incidental squamous cell carcinoma of the neovagina in Mayer-Rokitansky-Küster-Hauser syndrome. Gynecol Oncol. 2000 Apr; 77 (1):210-2.

88. Selvaggi SM, Haefner HK, Lelle RJ, Pearl ML, Roberts JA. Neovaginal cytology after total pelvic exenteration for gynecological malignancies. Diagn Cytopathol. 1995 Jul; 13 (1):22-5.

89. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD ,Kelsey Rogers W & Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institute of Health- National Heart, Lung, and Blood Institute sponsored women"s ischemia syndrome evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276–1284.

90. Steiner E, Woernle F, Kuhn W, Beckmann K, Schmidt M, Pilch H, Knapstein PG. Carcinoma of the neovagina: case report and review of the literature. Gynecol Oncol. 2002 Jan; 84 (1):171-5.

91. Tewari DS, McHale MT, Kuo JV, Monk BJ, Burger RA. Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome. Gynecol Oncol. 2002 May; 85 (2):384-7.

92. Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003.

93. Trappe HJ, Klein H, Frank G, Lichtlen PR. Rate-responsive pacing as compared to fixed-rate VVI pacing in patients after ablation of the atrioventricular conduction system. Eur Heart J. 1988 9(6) :642-8.

94. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, et al. Modi?ed APC resistance assay for patients on oral anticoagulants. Lancet 1994;344:1709.

95. Ursic-Vrscaj M, Lindtner J, Lamovec J, Novak J. Adenocarcinoma in a sigmoid neovagina 22 years after Wertheim-Meigs operation. Case report. Eur J Gynaecol Oncol. 1994; 15 (1):24-8.

96. Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:

97. Viscoli CM, Brass LM, et al. A clinical trial of estrogen replacement therapy after isquemic stroke. N Engl J Med 2001; 345: 1243-1249.

98. Vujovic S, Popovic S, Sbutega-Milosevic G, Djordjevic M, Gooren L (2009) Transsexualism in Serbia: a twenty-year follow-up study. J Sex Med 6: 1018–1023.

99. Wheelock JB, Schneider V, Goplerud DR. Malignancy arising in the transplanted vagina. South Med J. 1986 Dec; 79 (12):1585-7.

100. Wielgos M, Szymusik I, Banaszek A, Suchonska B, Kaminski P, Gadomska H, Bablok L. Cancer of the urinary bladder neovagina in a patient with Morris' syndrome. Onkologie. 2008 Feb; 31 (1-2):53-5.

101. Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C & Carr S. Effects of high dose oestrogen therapy on circulating in?ammatory markers. Maturitas 2009 62 281–286. (doi:10.1016/j.maturitas. 2009.01.009).

102. Wit AL, Rosen MR. Pathophysiologic mechanisms of cardiac arrhythmias. Am Heart J 1983; 106: 798-811.